[Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET]
- PMID: 19627018
[Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET]
Abstract
Objective: To evaluate the value of dual time point 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in differentiating malignant and benign superficial lymph nodes.
Methods: Sixty-eight patients with ninety superficial lymph nodes were examined. Whole body 18F-FDG PET imaging was performed one hour (early) after FDG injection and repeated one hour (delayed) later but only for the interesting areas. The maximum standardized uptake value (SUVmax) was determined for each of the node on both early and delayed images (SUV early and SUV delayed, respectively). Retention index (RI) was then calculated. The cutoff values of SUV early, SUV delayed and RI were determined by receiver operating characteristic (ROC) analyses. The efficacy of each parameter was also analyzed by ROC analyses.
Results: The histopathology examinations confirmed 51 malignant nodes and 39 benign nodes. The SUV early (x +/- s) for benign nodes and malignant nodes were 3.26 +/- 1.62 and 8.04 +/- 5.56, respectively (P=0.000). The SUV delayed for benign nodes and malignant nodes were 3.93 +/- 2.11 and 9.82 +/- 6.29, respectively (P=0.000). The RI for benign nodes and malignant nodes were 19.1 +/- 22.5 and 24.8 +/- 18.8, respectively (P=0.191). The cutoff values of SUV early, SUV delayed and RI were 4.3, 4.8 and 18, respectively. The cutoff values of SUV early, SUV delayed and RI produced a sensitivity of 71%, 78% and 63%, a specificity of 87%, 85% and 46%, and an accuracy of 78%, 80% and 57%, respectively. The ROC analyses illustrated that the diagnostic efficacy of SUV early, SUV delayed was higher than RI (P<0.001). However, there was no difference in diagnostic efficacy between SUV early, and SUV delayed (P=0.409).
Conclusion: Dual-time point 18F-FDG PET does differentiate benign and malignant superficial lymph nodes effectively.
Similar articles
-
Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma.Eur J Radiol. 2012 May;81(5):1024-8. doi: 10.1016/j.ejrad.2011.03.018. Epub 2011 Apr 1. Eur J Radiol. 2012. PMID: 21458941
-
Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.Ann Nucl Med. 2008 May;22(4):245-50. doi: 10.1007/s12149-007-0103-2. Epub 2008 Jun 6. Ann Nucl Med. 2008. PMID: 18535874
-
Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.J Nucl Med. 2006 Apr;47(4):633-8. J Nucl Med. 2006. PMID: 16595497
-
Dual-time point 18F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations.Semin Nucl Med. 2017 Jul;47(4):373-391. doi: 10.1053/j.semnuclmed.2017.02.009. Epub 2017 Apr 19. Semin Nucl Med. 2017. PMID: 28583277 Review.
-
Diagnostic accuracy of SUVmax in predicting malignancy of supraclavicular lymph nodes from primary oesophageal cancer.Eur J Radiol. 2020 Apr;125:108860. doi: 10.1016/j.ejrad.2020.108860. Epub 2020 Feb 11. Eur J Radiol. 2020. PMID: 32065926 Review.
Cited by
-
18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.BMC Cancer. 2014 Jun 19;14:453. doi: 10.1186/1471-2407-14-453. BMC Cancer. 2014. PMID: 24942656 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical